Latest News and Press Releases

- Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes - - Parties will collaborate through commercialization and share costs and profits worldwide - ...

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD--Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018--Preclinical Studies for...

ZUG, Switzerland and CAMBRIDGE, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the...

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...

-On track to begin CTX001 clinical study in hemoglobinopathies in 2018--On track to file IND in 2018 for CTX101, allogeneic CRISPR-based CAR-T targeted toward CD19+ malignancies--$341.8 million in...

ZUG, Switzerland and CAMBRIDGE, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based...

-Off-the-shelf CAR-T candidates against BCMA and CD70 address both hematologic malignancies and solid tumors - -New data demonstrate high editing rates, consistent expression, selective and potent...

ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...